Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Iterum Therapeutics

Request full access

Pharmaceutical developing differentiated anti-infectives

Dublin, IrelandFounded 2015Biotech & Life Sciences

About Iterum Therapeutics

Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company focused on developing innovative anti-infective treatments. The company primarily targets multi-drug resistant (MDR) pathogens, which are bacteria that have become resistant to multiple antibiotics, posing a significant global health threat. Iterum's core product is a novel anti-infective compound that has shown potent activity against a wide range of gram-negative, gram-positive, and anaerobic bacteria in laboratory tests.

The company operates in the pharmaceutical and biotechnology market, serving healthcare providers, hospitals, and patients who are affected by serious and life-threatening infections. Iterum's business model revolves around the research, development, and commercialization of its proprietary anti-infective compounds. Revenue is generated through the sale of these pharmaceutical products, as well as potential partnerships and licensing agreements with other healthcare companies.

Iterum Therapeutics aims to address the urgent need for new antibiotics in the face of rising antibiotic resistance. By focusing on differentiated anti-infectives, the company seeks to improve patient outcomes and provide effective treatment options where existing antibiotics have failed.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2018

Iterum Therapeutics in the Dublin ecosystem

Live from Dealroom

The Iterum Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A10 investors entered at this stage

  • Canaan
  • New Leaf Venture Partners
  • Sofinnova Partners
  • Frazier Healthcare Partners
  • Arix Bioscience
  • Pivotal Life Sciences
  • Bay City Capital
  • Advent Life Sciences
  • Domain Associates
  • Sofinnova Investments

Series B and later1 investor entered at this stage

Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States66.7%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Iterum Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Iterum Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.